Neuroprotective Therapies for Glaucoma

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2015 Mar 21

PMID 25792807

Citations 27

Authors

Wei Song

Ping Huang

Chun Zhang

Affiliations

Soon will be listed here.

Abstract

Glaucoma is the second leading cause for blindness worldwide. It is mainly caused by glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which leads to visual field defect and blindness. Up to now, the main purpose of antiglaucomatous therapies has been to lower intraocular pressure (IOP) through surgeries and medications. However, it has been found that progressive GON is still present in some patients with effective IOP decrease. Therefore, risk factors other than IOP elevation, like neurotrophin deprivation and excitotoxicity, contribute to progressive GON. Novel approaches of neuroprotection may be more effective for preserving the function of the optic nerve.

Citing Articles

Lycium barbarum glycopeptide promotes neuroprotection in ET-1 mediated retinal ganglion cell degeneration.

Lakshmanan Y, Wong F, So K, Chan H J Transl Med. 2024; 22(1):727.

PMID: 39103918 PMC: 11302070. DOI: 10.1186/s12967-024-05526-8.

Molecular Mechanisms of Glaucoma Pathogenesis with Implications to Caveolin Adaptor Protein and Caveolin-Shp2 Axis.

Abbasi M, Gupta V, Chitranshi N, Moustardas P, Ranjbaran R, Graham S Aging Dis. 2023; 15(5):2051-2068.

PMID: 37962455 PMC: 11346403. DOI: 10.14336/AD.2023.1012.

Potential role of polysaccharides in glaucoma management: evidence from preclinical studies.

Lakshmanan Y, Wong F, So K, Chan H Neural Regen Res. 2023; 18(12):2623-2632.

PMID: 37449600 PMC: 10358649. DOI: 10.4103/1673-5374.355977.

Surgical Menopause Impairs Retinal Conductivity and Worsens Prognosis in an Acute Model of Rat Optic Neuropathy.

Olakowska E, Rodak P, Pacwa A, Machowicz J, Machna B, Lewin-Kowalik J Cells. 2022; 11(19).

PMID: 36231022 PMC: 9564175. DOI: 10.3390/cells11193062.

Rho Kinase Inhibitors as a Neuroprotective Pharmacological Intervention for the Treatment of Glaucoma.

Thomas N, Nagrale P Cureus. 2022; 14(8):e28445.

PMID: 36176819 PMC: 9512308. DOI: 10.7759/cureus.28445.

References

Narayanaswamy A, Baskaran M, Zheng Y, Lavanya R, Wu R, Wong W . The prevalence and types of glaucoma in an urban Indian population: the Singapore Indian Eye Study. Invest Ophthalmol Vis Sci. 2013; 54(7):4621-7. DOI: 10.1167/iovs.13-11950. View

Dang Y, Xu Y, Wu W, Li W, Sun Y, Yang J . Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-κB and ERK signaling pathways in BV2 cells. PLoS One. 2014; 9(8):e102522. PMC: 4130469. DOI: 10.1371/journal.pone.0102522. View

Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N . Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003; 48 Suppl 1:S25-37. DOI: 10.1016/s0039-6257(03)00005-5. View

Sposato V, Bucci M, Coassin M, Russo M, Lambiase A, Aloe L . Reduced NGF level and TrkA protein and TrkA gene expression in the optic nerve of rats with experimentally induced glaucoma. Neurosci Lett. 2008; 446(1):20-4. DOI: 10.1016/j.neulet.2008.09.024. View

Zhang S, Wei J, Li C, Barnstable C, Fu X . Expression and activation of STAT proteins during mouse retina development. Exp Eye Res. 2003; 76(4):421-31. DOI: 10.1016/s0014-4835(03)00002-2. View

Quaranta L, Bettelli S, Uva M, Semeraro F, Turano R, Gandolfo E . Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003; 110(2):359-62; discussion 362-4. DOI: 10.1016/S0161-6420(02)01745-1. View

Manev H, Favaron M, Guidotti A, Costa E . Delayed increase of Ca2+ influx elicited by glutamate: role in neuronal death. Mol Pharmacol. 1989; 36(1):106-12. View

Neufeld A . Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol. 1999; 117(8):1050-6. DOI: 10.1001/archopht.117.8.1050. View

Kerrigan L, Zack D, Quigley H, Smith S, Pease M . TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997; 115(8):1031-5. DOI: 10.1001/archopht.1997.01100160201010. View

10.

Adler R, Landa K, Manthorpe M, Varon S . Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science. 1979; 204(4400):1434-6. DOI: 10.1126/science.451576. View

11.

McKinnon S, Lehman D, Tahzib N, Ransom N, Reitsamer H, Liston P . Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002; 5(6):780-7. DOI: 10.1006/mthe.2002.0608. View

12.

Dreyer E, Zurakowski D, Schumer R, Podos S, Lipton S . Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996; 114(3):299-305. DOI: 10.1001/archopht.1996.01100130295012. View

13.

Quigley H, Broman A . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-7. PMC: 1856963. DOI: 10.1136/bjo.2005.081224. View

14.

Casson R, Chidlow G, Wood J, Crowston J, Goldberg I . Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012; 40(4):341-9. DOI: 10.1111/j.1442-9071.2012.02773.x. View

15.

Harper M, Grozdanic S, Blits B, Kuehn M, Zamzow D, Buss J . Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011; 52(7):4506-15. PMC: 3175938. DOI: 10.1167/iovs.11-7346. View

16.

Neufeld A, Das S, Vora S, Gachie E, Kawai S, Manning P . A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J Glaucoma. 2002; 11(3):221-5. DOI: 10.1097/00061198-200206000-00010. View

17.

Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y . Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res. 2000; 70(4):475-84. DOI: 10.1006/exer.1999.0809. View

18.

Chaudhary P, Ahmed F, Sharma S . MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 1998; 792(1):154-8. DOI: 10.1016/s0006-8993(98)00212-1. View

19.

Neufeld A, Hernandez M, Gonzalez M . Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997; 115(4):497-503. DOI: 10.1001/archopht.1997.01100150499009. View

20.

Levi-Montalcini R . The nerve growth factor 35 years later. Science. 1987; 237(4819):1154-62. DOI: 10.1126/science.3306916. View